EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Severity-dependent metabolic rewiring in COVID-19 based on untargeted metabolomic profiling of patient plasma

Marta Majewska iD, Mateusz A Maździarz, Ewa Lepiarczyk, Aleksandra Lipka, Marta Wiszpolska, Beata Moczulska, Elżbieta Łopieńska-Biernat, Piotr Iwanowicz, Piotr Kocbach, Hilde Galtung, Leszek Gromadziński

PLOS One · 25.06.2026 · 21 (6) · e0352437

DOI: 10.1371/journal.pone.0352437 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 25.06.2026. Verfasst von Marta Majewska und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Physiology and Pathophysiology, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Olsztyn, Polan…. Hauptthemen laut MEDLINE: COVID-19, Metabolomics, Metabolome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Uniwersytet Warmińsko-Mazurski w Olsztynie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a major global health challenge, characterised by a heterogeneous clinical spectrum. While metabolomic studies have identified disruptions in amino acid, lipid, nucleotide, and energy metabolism during COVID-19, these investigations often lack fine-grained clinical stratification. In this study, we performed untargeted metabolomic profiling of plasma from 25 participants, including five healthy controls and twenty COVID-19 patients classified into four severity groups (COV1–COV4) based on pulmonary involvement and the need for respiratory support. Using ultra-performance liquid chromatography coupled with mass spectrometry (UPLC-MS), 541 metabolites were detected and analysed across all samples. Principal component analysis revealed a progressive metabolic divergence corresponding to disease severity. Monocarboxylic acid dysregulation was predominant in early to moderate cases (COV1–COV3), whereas severe disease (COV4) demonstrated a shift toward pyrimidine metabolism enrichment, consistent with heightened nucleotide turnover driven by viral replication and immune cell proliferation. Phenylalanine metabolism emerged as a consistently enriched pathway in COV1–COV3, suggesting aromatic amino acid perturbations as early markers of metabolic stress and immune activation. In contrast, pyrimidine pathway activation in COV4 could reflect profound systemic metabolic reprogramming associated with critical illness. These findings provide novel insights into COVID-19 pathophysiology, highlighting stage-specific metabolic signatures and potential biomarkers for disease monitoring. Our results support the concept of metabolomics-guided precision medicine, offering a rationale for targeted therapeutic interventions based on disease stage and metabolic phenotype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19MetabolomicsMetabolomeHumansFemaleSARS-CoV-2MaleSeverity of Illness IndexMiddle AgedAgedAdultPandemicsCase-Control StudiesMetabolic ReprogrammingChromatography, High Pressure LiquidPrincipal Component Analysis

Autor:innen und Institutionen

  • Department of Human Physiology and Pathophysiology, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.
  • Department of Botany and Evolutionary Ecology, Faculty of Biology and Biotechnology, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.
  • Faculty of Dentistry, Institute of Oral Biology, University of Oslo, Oslo, Norway.
  • Department of Cardiology and Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.
  • Department of Biochemistry, Faculty of Biology and Biotechnology, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.
  • Diagnostyka Medical Laboratories, Olsztyn, Poland.

ORCID-Profile: Marta Majewska

Förderung

  • Uniwersytet Warmińsko-Mazurski w Olsztynie

Zitieren

APA

Majewska, M., Maździarz, M. A., Lepiarczyk, E., Lipka, A., Wiszpolska, M., Moczulska, B., Łopieńska-Biernat, E., Iwanowicz, P., Kocbach, P., Galtung, H., & Gromadziński, L. (2026). Severity-dependent metabolic rewiring in COVID-19 based on untargeted metabolomic profiling of patient plasma. PLOS One, 21(6), e0352437. https://doi.org/10.1371/journal.pone.0352437

Vancouver

Majewska M, Maździarz MA, Lepiarczyk E, Lipka A, Wiszpolska M, Moczulska B, et al. Severity-dependent metabolic rewiring in COVID-19 based on untargeted metabolomic profiling of patient plasma. PLOS One. 2026;21(6):e0352437. doi:10.1371/journal.pone.0352437

BibTeX
@article{Majewska2026,
  author = {Majewska, Marta and Maździarz, Mateusz A and Lepiarczyk, Ewa and Lipka, Aleksandra and Wiszpolska, Marta and Moczulska, Beata and Łopieńska-Biernat, Elżbieta and Iwanowicz, Piotr and Kocbach, Piotr and Galtung, Hilde and Gromadziński, Leszek},
  title = {Severity-dependent metabolic rewiring in COVID-19 based on untargeted metabolomic profiling of patient plasma},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {6},
  pages = {e0352437},
  doi = {10.1371/journal.pone.0352437}
}
Kostenlos starten →